Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Multinational, Prospective, Interventional, Single-arm, Phase IV Study Evaluating the Clinical Efficacy and Safety of 26 Weeks of Treatment With Insulin Glargine 300 U/mL (Gla-300) in Patients With Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin

NCT03760991 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT03760991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03760991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Multinational, Prospective, Interventional, Single-arm, Phase IV Study Evaluating the Clinical Efficacy and Safety of 26 Weeks of Treatment With Insulin Glargine 300 U/mL (Gla-300) in Patients With Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Completed
Start date
December 18, 2018
Completion date
September 23, 2020
Enrollment
372 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus